Resultado da Busca
4 de ago. de 2022 · Molecular characterization of colorectal cancer related peritoneal metastatic disease | Nature Communications. Article. Open access. Published: 04 August 2022. Molecular...
Há 3 dias · 3547 Background: Activating mutations in the MAPK pathway are predictive biomarkers in mCCR and 50% of patients (pts) present KRAS mutations. There is a large spectrum of molecular aberrations with a lack of data regarding tumor side correlations and their impact on treatment response and overall survival. Methods: Retrospective cohort of mCRC pts and KRAS activating mutations treated between ...
14 de mar. de 2024 · The Colorectal Cancer Subtyping Consortium established four Consensus Molecular Subtypes (CMS) in colorectal cancer: CMS1 (microsatellite-instability [MSI], Immune), CMS2 (Canonical, epithelial ...
- Jaime Feliu
2 de jun. de 2022 · 3535Background: Approximately 20% of colorectal cancer (CRC) has an activating mutation in the PIK3CA oncogene. PIK3CA codes for the catalytic subunit of phosphoinos... Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. | Journal of Clinical Oncology
23 de mai. de 2024 · To this end, we focused on colorectal cancer (CRC) as a paradigmatic example of a common malignancy. According to their molecular profiles, most CRCs are classified as microsatellite stable (MSS) tumors, are characterized by chromosomal instability and are usually associated with a proficient mismatch repair machinery (MMRp).
22 de jun. de 2022 · CRC involves genetic and epigenetic modifications in colonic epithelium, leading to colon adenocarcinoma. The current review highlights the pathogenic mechanisms and multifactorial etiology of CRC, influenced by apoptosis, inflammation, and autophagy pathways.
Coloncancer(CC)isthethirdleadingcauseofcancer-related death inadultpatientsintheUS.Anestimated106,180newCC cases and 52,580 deathsareexpected in2022. Althoughnew 1. 2 , treatments have 3 improved outcomes, thefiveyearrelativesurvival remains pooratonly64.7%. 2 Theoddsareworseforpatientswith.
